Diosmin therapy for chronic vein diseases in outpatient settings: results of non-intervention STATUS study

Stoyko Yu.M.

N.I. Pirogov National Medical and Surgical Center

SPIN RSCI: 8835-0076
Scopus AuthorID: 57217151957
ORCID: 0000-0002-3394-5858

Tsyplyashchuk A.V.

N.I. Pirogov National Medical and Surgical Center

ORCID: 0000-0003-4579-6113

Kryzhanovskiy S.M.

Central State Medical Academy of Department of Presidential Affairs

ORCID: 0000-0003-4010-4288

Markin S.M.

St. Petersburg Clinical Hospital of the Russian Academy of Sciences

ORCID: 0000-0002-4026-3863

Diosmin therapy for chronic vein diseases in outpatient settings: results of non-intervention STATUS study

Authors:

Stoyko Yu.M., Tsyplyashchuk A.V., Kryzhanovskiy S.M., Markin S.M.

More about the authors

Journal: Journal of Venous Disorders. 2020;14(3): 230‑236

DOI: 10.17116/flebo202014031230

Downloaded: 131

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Stoyko YuM, Tsyplyashchuk AV, Kryzhanovskiy SM, Markin SM. Diosmin therapy for chronic vein diseases in outpatient settings: results of non-intervention STATUS study. Journal of Venous Disorders. 2020;14(3):230‑236. (In Russ.)
https://doi.org/10.17116/flebo202014031230

Подписка 2025 (Journal of Venous Disorders)

Close metadata

OBJECTIVE

To evaluate physicians’ compliance with diosmin instructions and patients’ adherence to treatment, as well as to evaluate the prevalence of symptoms of chronic vein diseases (CVD) and the dynamics of their severity in the background of therapy.

MATERIAL AND METHODS. A

Prospective multicenter non-interventional (observational) study was carried out to evaluate the results of 600 mg diosmin administration during 2 months in patients over 18 years of C1—C3 CVD classes under CEAP with subjective symptoms. The proportion of patients to whom the drug was administered according to the recommended regimen was estimated. Patient’s adherence to and satisfaction with therapy were determined on the basis of a questionnaire. Objective and subjective symptoms of CVD were fixed, their severity was changed on the background of therapy. The frequency of undesirable phenomena was recorded.

THE RESULTS

Included in the study are 2013 patients: 1551 women and 462 men. The main pattern of administration was taking 1 tablet once a day (1964 patients). The recommendation to take 1 tablet 2 times a day was given to 49 (2.4%) patients. The recommended duration of administration ranged from 4 to 18 weeks, with 1795 patients (89.2%) receiving the course at 8 weeks. By the second visit, 9.7% of patients missed an average of 2.2±1.3 doses, and by the third visit — 2.4±1.6 doses were missed by 8.3% of patients. Expression of the CVD symptom-complex (all symptoms in total) before treatment was 6.0±1.85 points, at the second visit — 4.2±1.65, at the third visit — 2.3±1.60 points. In 1 month of treatment 10.6% reported complete disappearance of subjective symptoms, in 2 months — 225 (11.4%). The satisfaction with the therapy was high. Unwanted events were registered in 1.99% of patients, while a clear or possible relationship with the drug was established in 0.55% of cases.

CONCLUSIONS

The vast majority of doctors recommend diosmin according to the instructions for its use. Taking the drug in a dose of 600 mg/day leads to a decrease in the severity of subjective symptoms and swelling. Patients’ adherence to and satisfaction with the therapy is high.

Keywords:

chronic vein disease

diosmin

surveillance study

Authors:

Stoyko Yu.M.

N.I. Pirogov National Medical and Surgical Center

SPIN RSCI: 8835-0076
Scopus AuthorID: 57217151957
ORCID: 0000-0002-3394-5858

Tsyplyashchuk A.V.

N.I. Pirogov National Medical and Surgical Center

ORCID: 0000-0003-4579-6113

Kryzhanovskiy S.M.

Central State Medical Academy of Department of Presidential Affairs

ORCID: 0000-0003-4010-4288

Markin S.M.

St. Petersburg Clinical Hospital of the Russian Academy of Sciences

ORCID: 0000-0002-4026-3863

Received:

30.06.2020

Accepted:

10.07.2020

List of references:

Russian Guidelines on Diagnostics and Treatment of Chronic Venous Disease. Flebologiya. 2013;7(2-2):1-47. (In Russ.).
Zolotukhin IA, Seliverstov EI, Shevtsov YN, Avakiants IP, Nikishkov AS, Tatarintsev AM, et al. Prevalence and Risk Factors for Chronic Venous Disease in the General Russian Population. Eur J Vasc Endovasc Surg. 2017;54(6):752-758. Accessed July 2, 2020. https://www.ncbi.nlm.nih.gov/pubmed/29031868
Kirienko AI, Zolotukhin IA, Yumin SM, Seliverstov EI. Lower limb varicose disease in men and women: findings of prospective study SPECTRUM. Angiology and Vascular Surgery. 2012;18(3):64-68. (In Russ.).
Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Community Health. 1999;53(3):149-153. Accessed July 2, 2020. https://www.ncbi.nlm.nih.gov/pubmed/10396491
Labropoulos N, Leon L, Kwon S, Tassiopoulos A, Gonzalez-Fajardo JA, Kang SS, Mansour MA, Littooy FN. Study of the venous reflux progression. J Vasc Surg. 2005;41(2):291-295.
Bergan J. Molecular mechanisms in chronic venous insufficiency. Ann Vasc Surg. 2007;21(3):260-266. Accessed 2, 2020. https://www.ncbi.nlm.nih.gov/pubmed/17484957
Lim CS, Davies AH. Pathogenesis of primary varicose veins. Br J Surg. 2009;96(11):1231-1242.
Perrin M, Eklöf B, Van Rij A, Labropoulos N, Vasquez M, Nicolaides A, Blattler W, Bouhassira D, Bouskela E, Carpentier P, Darvall K, DE Maeseneer M, Flour M, Guex JJ, Hamel-Desnos C, Kakkos S, Launois R, Lugli M, Maleti O, Mansilha A, Neglén P, Rabe E, Shaydakov E. Venous symptoms: the SYM Vein Consensus statement developed under the auspices of the European Venous Forum. Int Angiol. 2016;35(4):374-398. Accessed 2, 2020. https://www.minervamedica.it/en/journals/international-angiology/article.php?cod=R34Y2016N04A0374
Bogucka-Kocka A, Woźniak M, Feldo M, Kockic J, Szewczyk K. Diosmin — isolation techniques, determination in plant material and pharmaceutical formulations, and clinical use. Nat Prod Commun. 2013;8(4):545-550.
Germoush M. Diosmin protects against cyclophosphamide-induced liver injury through attenuation of oxidative stress, inflammation and apoptosis. Intl J Pharmacol. 2016;12(6):644-654.
Zuccarelli F. Diovenor 300. Etude de l’activité thérapeutique pendant 3 mois sur les oedèmes des membres inférieurs liés à une maladie veineuse fonctionnelle ou organique. Tribune Médicale. 1990;343:44-49.
Maruszynski M, Staszkiewicz W, Andziak P. A double blind, randomized study evaluating the influence of semisynthetic diosmin, and purified, micronized flavonoid fraction (diosmin and hesperidin), on symptoms of chronic venous insufficiency of lower limbs — a four week observation. Prz Flebol. 2004;12(3):89-95.
Cazaubon M, Bailly C, Ducros E, Lancrenon S. Acceptability, efficacy and safety of two pharmaceutical forms of diosmin 600 mg in patients with chronic venous disease: a randomized comparative multicenter study. Angiology. 2011;63(2):35-42.
Henriet J-P. Insuffisance veineuse fonctionnelle: essai clinique comparatif d’une seule prise par jour de Diovenor 600 mg (600 mg de diosmine d’hemisynthese) versus 2 prises par jour d’un melange de 500 mg de flavonoids (900 mg de diosmine). Phlebologie. 1995;48(2):2-7.
Stoĭko YuM, Talibov OB, Iashkin MN, Kudykin MN, Belentsov SM, Katel’nitskaia OV, Suchkov IA, Tolstikhin VYu, Kletskin AÉ, Sevost’ianova KS. Multicentre observational study of Phlebodia 600 in treatment of patients with CEAP class C0-C3 chronic venous diseases. Angiol Sosud Khir. 2018; 24(1):107-113. (In Russ.).
Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X. Phlebotonics for venous insufficiency. In: Martinez-Zapata MJ, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2016. Accessed 2, 2020. https://www.ncbi.nlm.nih.gov/pubmed/27048768

Close metadata